## 2023 – 2024 Influenza A Sequence Surveillance Assessment for BIOFIRE® FILMARRAY® and BIOFIRE® SPOTFIRE® Respiratory Solutions

#### Introduction

The BIOFIRE® FILMARRAY® and BIOFIRE® SPOTFIRE® Respiratory Solutions include multiplexed PCR-based in vitro diagnostic tests for the detection of nucleic acids of viruses and bacteria in upper and lower respiratory specimens and are intended to aid in the diagnosis of respiratory infections, including pneumonia.

The BIOFIRE FILMARRAY Respiratory Solutions, including the BIOFIRE® Respiratory 2.1 (RP2.1) Panel, BIOFIRE® Respiratory 2.1*plus* (RP2.1*plus*) Panel, BIOFIRE® FILMARRAY® Pneumonia (PN) Panel, and BIOFIRE® FILMARRAY® Pneumonia *plus* (PN*plus*) Panel, are intended to be used as indicated in moderate- and highcomplexity laboratories. The BIOFIRE SPOTFIRE Respiratory Solutions, including BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel, BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini, BIOFIRE® SPOTFIRE® Respiratory (R) Panel and BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini, are intended to be used as indicated in moderate- and high-complexity laboratories. The BIOFIRE SPOTFIRE Respiratory Solutions are also cleared for use in CLIA-waived settings.

Each BIOFIRE Panel includes one or more assays for the detection of influenza A viruses. The influenza A virus results reported by each panel (including haemagglutinin (HA) subtype, if applicable) are indicated in Table 1.

System	Product	Influenza A Virus Reporting	
BIOFIRE FILMARRAY	BIOFIRE RP2.1/RP2.1 <i>plus</i> Panels	Influenza A virus Influenza A virus A/H1 Influenza A virus A/H1-2009 Influenza A virus A/H3	
	<b>BIOFIRE PN/PNplus Panels</b>	Influenza A virus	
BIOFIRE SPOTFIRE	SPOTFIRE R/ST Panel	Influenza A virus Influenza A virus A/H1-2009 Influenza A virus A/H3	
	SPOTFIRE R/ST Panel Mini	Influenza A virus	
	SPOTFIRE R Panel	Influenza A virus Influenza A virus A/H1-2009 Influenza A virus A/H3	
	SPOTFIRE R Panel Mini	Influenza A virus	

Table 1. Influenza A Virus Reporting for BIOFIRE FILMARRAY and BIOFIRE SPOTFIRE Respiratory Solutions Products.

Influenza A viruses have a single-stranded segmented RNA genome, and the low-fidelity viral RNA polymerase causes continuous genetic mutation and evolution as the virus replicates. Consequently, the genome sequence of influenza A viruses circulating and infecting humans changes over time. Seasonal or global pandemics can arise

Attachment 2 of LLDC 069952 - Rev 01.A Old Document Reference QS-339J-01 BFR0002-5862-02



### TECHNICAL ::: NOTE

when antigenic drift (small mutations in viral genes that can lead to changes in surface proteins) and antigenic shift (major mutations resulting in new surface proteins in viruses that infect humans) lead to the emergence of a novel influenza A virus in a population where there is little to no immunity. Viral genetic variation and evolution can also affect the ability of sequence-based diagnostic tests to accurately identify the virus in clinical specimens. Therefore, it is important for manufacturers of influenza A virus diagnostic tests to monitor the genetic changes in the virus over time to assess whether the test continues to be safe and effective for its intended purpose.


#### Surveillance of 2023-2024 Influenza A Virus Sequences

To monitor for emerging variant viruses with genetic changes that may alter detection of influenza A viruses by the BIOFIRE Panels, bioMérieux regularly (at least annually) assesses newly available influenza A virus sequence data from the Global Initiative on Sharing All Influenza Data (GISAID) database and other sources where appropriate. Sequences are aligned to the influenza A virus assay primers, allowing for sequence-based predictions of reactivity with each assay and identification of potential sequence-dependent limitations on reactivity (referred to as in-silico analysis). Sequence-based assay specificity (risk of cross-reactivity with non-influenza A virus sequences) is also evaluated annually.

In silico analysis for pan-influenza A assays include all available sequences of the targeted genes from human H1N1/H1N1pdm09, H1N2, and H3N2 virus subtypes as well as sequences of influenza viruses of avian and swine origin. The most recent surveillance in silico reactivity assessment for influenza A virus was performed on >40,000 pan-influenza A virus and approximately 20,000 haemagglutinin subtype sequences deposited to the GISAID database from June 1, 2023 to June 30, 2024. Predicted assay reactivity for each panel (percent (%) and number of total sequences predicted to be efficiently amplified by an assay) is presented in Table 2.

Table 2. Predicted Reactivity of Influenza A Virus Sequences for BIOFIRE FILMARRAY and BIOFIRE SPOTFIRE
Respiratory Solutions Products.

	BIOFIRE Respiratory Solutions			
Influenza A assay/assay group	BIOFIRE FILMARRAY RP2.1/RP2.1 <i>plus</i> Panels	BIOFIRE FILMARRAY PN/PN <i>plus</i> Panels	BIOFIRE SPOTFIRE R/ST and R Panels	BIOFIRE SPOTFIRE R/ST Panel Mini and R Panel Mini
FluA	-	<b>99.1%</b> (44,588/44,971ª)	-	-
Pan-FluA assays	<b>99.1%</b> (44,588/44,971ª)	-	<b>99.1%</b> (44,588/44,971ª)	-
	<b>99.6%</b> (42,356/42,491 <sup>b</sup> )	-	<b>99.6%</b> (42,356/42,491 <sup>b</sup> )	-
H1 subtype <sup>f</sup>	<b>N/A</b> (0/0)	-	-	-
H1-2009 subtype	<b>94.5%</b> ° (25,163/26,628)	-	<b>94.5%</b> <sup>d</sup> (25,163/26,628)	-
H3 subtype	<b>99.9%</b> (19,371/19,381)	-	<b>99.9%</b> (19,371/19,381)	-
Group 1	-	-	-	<b>99.1%</b> (44,588/44,971ª)
assays	-	-	-	<b>99.6%</b> (42,356/42,491 <sup>b</sup> )
Group 2 assays	-	-	-	<b>94.5%</b> ° (25,163/26,628)
	-	-	-	<b>99.9%</b> (19,371/19,381)





### TECHNICAL ::: NOTE

<sup>a</sup> Represents 24,739 sequences of influenza A H1 subtype, 17,164 sequences of influenza A H3 subtype, 13 sequences of Influenza A H5N1 subtype, 712 sequences of swine origin, 2,343 sequences of avian origin.

<sup>b</sup> Represents 23,340 sequences of influenza A H1 subtype, 16,079 sequences of influenza A H3 subtype, 12 sequences of Influenza A H5N1 subtype, 734 sequences of swine origin, 2,319 sequences of avian origin.

° 1,268 (4.8%) H1-09 sequences of human origin are predicted to react with both Pan-FluA assays and will be reported as "Influenza A Virus, (no subtype detected)" on the BIOFIRE FILMARRAY RP2.1/RP2.1*plus* panels.

<sup>d</sup> 1,268 (4.8%) H1-09 sequences of human origin are predicted to react with both Pan-FluA assays and will be reported as "Influenza A Virus, (no subtype identified)" on the BIOFIRE SPOTFIRE R/ST and R panels.

<sup>e</sup> 1,268 (4.8%) H1-09 sequences of human origin are predicted to react with both Group 1 assays and will be reported as "Influenza A virus, Uncertain" on the BIOFIRE SPOTFIRE R Panel Mini and BIOFIRE SPOTFIRE R/ST Panel Mini.
<sup>f</sup> No sequences for the H1 subtype were deposited into the GISAID database during the surveillance period (June 1, 2023 – June 30, 2024); however, in the previous surveillance period (October 1, 2022 – May 31, 2023) the Influenza A H1 assay was predicted to react with 97.7% (127/130) of the deposited sequences.

This in silico analysis reveals that the pan-influenza A virus assays (FluA, Pan-FluA, and Group1) in the BIOFIRE Respiratory Solutions panels are predicted to be reactive with >99% of the influenza A virus sequences (of human, avian and swine origin) deposited to the GISAID database during the 2024 - 2025 respiratory season. The subtype assay for Influenza A H3 is also predicted to be reactive with >99% of the total H3 database sequences. The subtype assay for Influenza A H1-09 is predicted to be reactive with 94.5% of the total H1-09 database sequences. An additional 4.8% (1,268/26,628) of the Influenza A H1-09 sequences are predicted to be reactive with both of the pan-influenza A virus assays providing either an Influenza A "no subtype detected" or "uncertain" result. The prevalence of sequences that would be predicted to have a minor (>3x) to major ( $\geq$ 10x) impact on amplification, detection, and/or reporting of influenza A virus is less than 1%.

In future annual analyses, if a variant sequence that is predicted to impact reactivity (>10-fold) represents 5% or more of the annual deposited sequences, the potential impact on amplification, detection and reporting by each panel will be investigated. If the investigation confirms a limitation on reactivity with one or more assays that would alter panel performance, a notification about the impact on test performance will be released and distributed.

**NOTE:** Testing with BIOFIRE FILMARRAY and BIOFIRE SPOTFIRE Panels containing assays for the detection of influenza A virus (and viral subtype sequences) is not intended to monitor for or identify novel variant viral strains of public health concern nor potential zoonotic transmission events.

# In Silico Reactivity Assessment of Influenza A Virus Strains Recommended for 2024-2025 Influenza Vaccine

The World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) recommends the composition of influenza virus vaccines biannually based on global surveillance data. The recommended influenza A virus strains to include in vaccines for use in the 2024-2025 northern hemisphere influenza season are:

H1N1pdm09:	A/Victoria/4897/2022 (egg-based vaccines)
	A/Wisconsin/67/2022 (cell-based or recombinant vaccines)
H3N2:	A/Thailand/8/2022 (egg-based vaccines)
	A/Massachusetts/18/2022 (cell-based or recombinant vaccines)

bioMérieux evaluated each of the recommended influenza A virus vaccine strain sequences against respective BIOFIRE FILMARRAY and BIOFIRE SPOTFIRE Panel pan-influenza A or subtype assay(s) and no reactivity limitations for vaccine strains were predicted by in silico analysis. Consequently, the panels are predicted to detect nucleic acids from vaccines if present in the specimens being tested.


> Attachment 2 of LLDC 069952 - Rev 01.A Old Document Reference QS-339J-01 BFR0002-5862-02



### TECHNICAL ::: NOTE

### Conclusion

- Influenza A virus assays in BIOFIRE FILMARRAY and BIOFIRE SPOTFIRE Panels are predicted to react with >99% of influenza A virus sequences deposited to the GISAID database from June 1, 2023 to June 30, 2024.
- bioMérieux has a surveillance program in place to evaluate newly deposited influenza A virus sequences. This active annual sequence surveillance program, along with other post-market monitoring activities, allows bioMérieux to maintain claims of state-of-the-art performance for detection and (subtyping) of influenza A virus in upper and lower respiratory specimens with BIOFIRE FILMARRAY and BIOFIRE SPOTFIRE Panels and to notify users if new deficiencies or limitations on influenza A virus detection are identified.







### **Technical Support Contact Information**

bioMérieux is dedicated to providing the best customer support available. If you have any questions or concerns about this process, please contact the BIOFIRE Technical Support team for assistance.

BIOFIRE Technical Support Email: biofiresupport@biomerieux.com Phone: +1-801-736-6354

\*All product names, trademarks and registered trademarks are property of their respective owners.

